Sanofi's IL-4/IL-13 mono-anti-Dupixent shows significant benefits in children with asexual dermatitis

Sanofi has released Phase III experimental data for its IL-4/IL-13 mono-anti-Dupixent (dupilumab) treatment for children with severe asexual dermatitis beyond controlThe results of the Phase III trial show edified by using Dupixent in combination with clinical lysage standard topical corticosteroids (TCS) to significantly alleviate the symptoms of disease in patients aged 6-11 years of severe asymptomatic dermatitisat week 16, three times as many children received clear or almost transparent skin as in children who received dupixent and TCS combination therapy were using TCS alone, and more than two-thirds of children's diseases improved by at least 75 percent overalland, in children receiving a combination of Dupixent and TCS treatment, the number of children with skin itching symptoms decreased was more than three times as high as the use of TCS aloneDupixent observed an improvement in itching and disease severity as early as two weeks after the first administration, and continued throughout active treatmentIn terms of safety, the overall incidence of adverse reactions in Dupixent was 65 per cent per four weeks, 67 per cent per two weeks, and the incidence of TCS alone was 73 per centDupixent is an all-human monoclonal antibody that inhibits the signaling of leukin 4 (IL-4) and leukin 13 (IL-13) proteinsIL-4/IL-13 plays a major role in the accompanying nasal polyps of asexual dermatitis, asthma and chronic sinusitisthe drug was developed jointly by Sanofi and Regeneration